普伐他汀治疗早发型子痫前期:随机双盲安慰剂对照试验
英国15家产科单位开展双盲、原理验证、安慰剂对照试验,62例早发型子痫前期孕妇(孕24+0至31+6周)随机接受普伐他汀40 mg每日或安慰剂至分娩。随机化后前3天平均血浆sFlt-1水平两组差异为292 pg/ml(95%CI -1175至592;P=0.5),前1-14天差异为48 pg/ml(95%CI -1009至913;P=0.9);普伐他汀组与安慰剂组随机化后妊娠持续时间相似(风险比0.84;95%CI 0.50-1.40;P=0.6)。作者结论:一旦发生早发型子痫前期,未发现普伐他汀降低母体血浆sFlt-1水平的证据;普伐他汀似乎无不良围产期影响。
要点
- 早发型子痫前期孕妇随机接受普伐他汀40 mg每日或安慰剂,前3天sFlt-1差异292 pg/ml(95%CI -1175至592;P=0.5)。
- 前1-14天sFlt-1差异48 pg/ml(95%CI -1009至913;P=0.9),未达统计学显著。
- 随机化后至分娩中位时间普伐他汀组9天(IQR 5-14)vs安慰剂组7天(IQR 4-11),风险比0.84(95%CI 0.50-1.40;P=0.6)。
核心结论
- 未发现普伐他汀在早发型子痫前期发生后降低母体血浆sFlt-1水平的证据。
- 普伐他汀似乎无不良围产期影响。
研究设计与样本
- 双盲(临床医生和受试者)、原理验证、安慰剂对照试验,在英国15家产科单位开展。
- 采用最小化算法将62例早发型子痫前期孕妇(孕24+0至31+6周)随机分配至普伐他汀40 mg每日组(n=30)或匹配安慰剂组(n=32),从随机化至分娩。
- 主要结局为随机化后前3天平均血浆sFlt-1水平的差异。
主要发现
- 随机化后前3天平均母体血浆sFlt-1水平普伐他汀组(n=27)与安慰剂组(n=29)差异为292 pg/ml(95%CI -1175至592;P=0.5)。
- 随机化后第1-14天sFlt-1水平差异为48 pg/ml(95%CI -1009至913;P=0.9)。
- 随机化后妊娠持续时间普伐他汀组与安慰剂组相似(风险比0.84;95%CI 0.50-1.40;P=0.6)。
- 随机化至分娩中位时间普伐他汀组9天(IQR 5-14天)vs安慰剂组7天(IQR 4-11天)。
- 安慰剂组发生3例围产期死亡,普伐他汀组无死亡或可归因于普伐他汀的严重不良事件。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Women with pre-eclampsia have elevated circulating levels of soluble fms-like tyrosine kinase-1 (sFlt-1). Statins can reduce sFlt-1 from cultured cells and improve pregnancy outcome in animals with a pre-eclampsia-like syndrome. We investigated the effect of pravastatin on plasma sFlt-1 levels during pre-eclampsia. DESIGN: Blinded (clinician and participant), proof of principle, placebo-controlled trial. SETTING: Fifteen UK maternity units. POPULATION: We used a minimisation algorithm to assign 62 women with early-onset pre-eclampsia (24+0 -31+6 weeks of gestation) to receive pravastatin 40 mg daily (n = 30) or matched placebo (n = 32), from randomisation to childbirth. PRIMARY OUTCOME: Difference in mean plasma sFlt-1 levels over the first 3 days following randomisation. RESULTS: The difference in the mean maternal plasma sFlt-1 levels over the first 3 days after randomisation between the pravastatin (n = 27) and placebo (n = 29) groups was 292 pg/ml (95% CI -1175 to 592; P = 0.5), and over days 1-14 was 48 pg/ml (95% CI -1009 to 913; P = 0.9). Women who received pravastatin had a similar length of pregnancy following randomisation compared with those who received placebo (hazard ratio 0.84; 95% CI 0.50-1.40; P = 0.6). The median time from randomisation to childbirth was 9 days (interquartile range [IQR] 5-14 days) for the pravastatin group and 7 days (IQR 4-11 days) for the placebo group. There were three perinatal deaths in the placebo-treated group and no deaths or serious adverse events attributable to pravastatin. CONCLUSIONS: We found no evidence that pravastatin lowered maternal plasma sFlt-1 levels once early-onset pre-eclampsia had developed. Pravastatin appears to have no adverse perinatal effects. TWEETABLE ABSTRACT: Pravastatin does not improve maternal plasma sFlt-1 or placental growth factor levels following a diagnosis of early preterm pre-eclampsia #clinicaltrial finds.
引用
- Ahmed A, Williams DJ, Cheed V, et al. Pravastatin for early-onset pre-eclampsia: a randomised, blinded, placebo-controlled trial. BJOG. 2019. PMID: 31715077. doi:10.1111/1471-0528.16013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。